跳至主要内容
临床试验/NCT05546372
NCT05546372招募中不适用

Endobiliary Radiofrequency Ablation for Malignant Biliary Obstruction Due to Perihilar Cholangiocarcinoma: a Randomized Controlled Trial

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)2 个研究点 分布在 1 个国家目标入组 122 人开始时间: 2022年10月22日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
122
试验地点
2
主要终点
Time to biliary obstruction

研究概览

简要总结

A multicentre, parallel group, open label, randomized controlled trial comparing endobiliary RFA prior to metal stent placement with stent placement only in patients with inoperable perihilar cholangiocarcinoma.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18 years or older.
  • Capable of providing written and oral informed consent.
  • Histological or cytological proof of perihilar CCA (adenocarcinoma).
  • Perihilar biliary obstruction with an indication for drainage with uSEMS.*
  • Advanced (no candidate for surgical resection) due to metastases, vascular or lymph node (N2) involvement on imaging or during staging laparoscopy according to multidisciplinary team (MDT).
  • Only patients with pCCA are eligible however in case of reasonable doubt between intrahepatic CCA with a perihilar biliary obstruction or massforming pCCA, patients can be included.

排除标准

  • Patients who potentially qualify for curative resection of pCCA.
  • pCCA eligible for liver transplantation.
  • Life-expectancy less than 3 months.
  • ERCP and PTC technically not feasible.
  • Uncontrolled coagulopathy (PTT >1,5x prolonged or thrombocytes below 40*10E9/L).
  • Ongoing cholangitis or liver abscess. Patients are required to be off antibiotic treatment for cholangitis and/or liver abscess at least 7 days.
  • Any condition that is unstable or that could jeopardize the safety of the subject and their compliance in the study.
  • Patients who are pregnant or breastfeeding.

研究组 & 干预措施

Endobiliary RFA + stent placement

Experimental

干预措施: Endobiliary radiofrequency ablation (eRFA) (Device)

Endobiliary RFA + stent placement

Experimental

干预措施: uncovered self-expanding metal stent (uSEMS) (Device)

Stent placement only

Active Comparator

干预措施: uncovered self-expanding metal stent (uSEMS) (Device)

结局指标

主要结局

Time to biliary obstruction

时间窗: Through study completion, max 1 year

Defined as period between initial procedure and recurrence of biliary obstruction. Recurrence of biliary obstruction is defined as recurrent jaundice (conjugated bilirubin ≥ 40 umol/l (≥2.3 mg/dl)), presence of biochemical evidence of cholestasis along with dilatation of the drained bile duct(s), or endoscopic findings suggesting stent occlusion.

次要结局

  • Stent patency after repeated eRFA.(Through study completion, an average of 1 year)
  • Quality of life expressed in quality adjusted life-years (QALYs)(Through study completion, max 1 year)
  • Number of patients with technical success of initial ablation(During intervention)
  • Need for external drainage catheters.(Through study completion, an average of 1 year)
  • Adverse events within 30 days after the procedu(30 days)
  • Presumed reason of recurrent biliary obstruction(Through study completion, an average of 1 year)
  • Overall survival.(Through study completion)
  • Healthcare costs.(Through study completion, max 1 year)
  • Number of patients with functional success(14 days)
  • Need for unscheduled re-intervention (PTC and/or ERCP) to achieve adequate biliary drainage.(Through study completion, an average of 1 year)
  • Time to re-intervention.(Through study completion, an average of 1 year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Rogier P. Voermans

Principal Investigator

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

研究点 (2)

Loading locations...

相似试验